152 related articles for article (PubMed ID: 2114029)
1. [A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment].
Agounitestane D; Chiheb M; Khaled S; Ait Khaled N; Boulahbal F; Chaulet P
Rev Mal Respir; 1990; 7(3):209-13. PubMed ID: 2114029
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic trial of a combination of isoniazid, rifampicin and pyrazinamide in the first 2 months of treatment of pulmonary tuberculosis].
Bellabas M; Khaled S; Khaled NA; Boulahbal F; Chaulet P
Rev Mal Respir; 1989; 6(1):59-64. PubMed ID: 2648511
[TBL] [Abstract][Full Text] [Related]
3. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
[TBL] [Abstract][Full Text] [Related]
4. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report.
Teo SK
Int J Tuberc Lung Dis; 1999 Feb; 3(2):126-32. PubMed ID: 10091877
[TBL] [Abstract][Full Text] [Related]
5. [Controlled study comparing 3 daily chemotherapy regimens for six months in pulmonary tuberculosis in routine practice in Algiers. Results at 30 months].
Mazouni L; Tazir M; Boulahbal F; Chaulet P
Rev Mal Respir; 1985; 2(4):209-14. PubMed ID: 3937189
[TBL] [Abstract][Full Text] [Related]
6. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):707-12. PubMed ID: 1901200
[TBL] [Abstract][Full Text] [Related]
7. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.
Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):700-6. PubMed ID: 1901199
[TBL] [Abstract][Full Text] [Related]
8. Bacteriological investigations for short-course chemotherapy under the tuberculosis programme in two districts of India.
Paramasivan CN; Chandrasekaran V; Santha T; Sudarsanam NM; Prabhakar R
Tuber Lung Dis; 1993 Feb; 74(1):23-7. PubMed ID: 8495016
[TBL] [Abstract][Full Text] [Related]
9. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
10. Fixed dose combination short course chemotherapy in the treatment of pulmonary tuberculosis.
Wolde K; Lema E; Roscigno G; Abdi A
Ethiop Med J; 1992 Apr; 30(2):63-8. PubMed ID: 1345030
[TBL] [Abstract][Full Text] [Related]
11. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
Su WJ; Perng RP
Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
[TBL] [Abstract][Full Text] [Related]
12. [Results of a therapeutic trial comparing a 6-month regimen to a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Final report: results 3 years after the onset of treatment].
Berkani M; Chaulet P; Darbyshire JH; Nunn A; Fox W
Rev Mal Respir; 1986; 3(2):73-85. PubMed ID: 3726263
[TBL] [Abstract][Full Text] [Related]
13. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
[TBL] [Abstract][Full Text] [Related]
14. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
Nolan CM; Goldberg SV
Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
[TBL] [Abstract][Full Text] [Related]
15. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of 3 6-month chemotherapy regimes in pulmonary tuberculosis in routine practice in Algiers. 18th-month results].
Chaulet P; Boulahbal F; Ait Khaled N; El Awadi Z; Tazir M
Rev Fr Mal Respir; 1983; 11(5):667-76. PubMed ID: 6658153
[TBL] [Abstract][Full Text] [Related]
17. Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin.
Moulding TS; Le HQ; Rikleen D; Davidson P
Int J Tuberc Lung Dis; 2004 Jun; 8(6):743-8. PubMed ID: 15182145
[TBL] [Abstract][Full Text] [Related]
18. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Am Rev Respir Dis; 1988 May; 137(5):1147-50. PubMed ID: 2904237
[TBL] [Abstract][Full Text] [Related]
19. [In 76% of patients with active tuberculosis treated with triple therapy (isoniazid-rifampicin-pyrazinamide) cultural conversion precedes microscopic conversion].
Nowak D; Radenbach D; Magnussen H
Pneumologie; 1990 Feb; 44 Suppl 1():497-8. PubMed ID: 2114634
[TBL] [Abstract][Full Text] [Related]
20. [Six-month short course chemotherapy containing pyrazinamide for initial treatment of pulmonary tuberculosis].
Wada M; Yosiyama T; Yosikawa M; Ogata H; Sugie T; Nakasono T; Sugita H
Kekkaku; 1994 Nov; 69(11):671-80. PubMed ID: 7837720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
